Vale SA vs GeneDx Holdings Corp — how do they compare? Vale SA trades at $14.13 (market cap $59.07B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Vale SA is far larger — about 32.8× GeneDx Holdings Corp's market cap, and Vale SA pays a 8.93% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| VALE | WGS | |
|---|---|---|
Market Cap | $59.07B | $1.80B |
Sector | Basic Materials | Technology |
52-Week High | $17.82 | $167.51 |
52-Week Low | $9.53 | $34.51 |
Enterprise Value | $75.99B | $1.80B |
Dividend Yield | 8.93% | — |
Signals from Pluang's Aura AI — not financial advice
VALE trades at $14.25, up 0.42% today but down 11% over the past month. Technical indicators show a bearish trend with moving averages signaling sell pressure. Fundamentally, revenue declined to $38.4B in 2025 with net income falling to $2.35B, though cash flow improved to $2.42B. Recent news highlights board governance disputes and a $2.6B decarbonization investment announced in June 2026.
The outlook remains cautious with mixed analyst ratings (40.5% buy, 48.7% hold) and a $17.13 consensus target. Risks include volatile iron ore prices and execution challenges, but stable cash flow and low debt provide some resilience. Upside depends on commodity demand recovery and cost management.
No Aura AI signal available yet.
Trailing returns across standard periods
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →